Presentations

Presentations

BARDA INDUSTRY DAY 2020
October 27th, 2020 | VIRTUAL EVENT
PRESENTATION
& TIMING
PRESENTERS
MORNING & PROGRAM OVERVIEW SESSIONS
00:04:20 – 00:19:00 Watch: ASPR WELCOME! – Dr. Robert Kadlec, M.D., MTM&H, M.S.: Assistant Secretary for Preparedness and Response
00:19:00 – 00:37:15 Watch: HIGHLIGHTED GOVERNMENT PARTNER – Mr. Douglas Bryce, Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)
00:37:15 – 00:50:36 Watch: INDUSTRY PARTNER –Evan Loh, M.D.: Chief Executive Office Paratek Pharmaceuticals
00:50:36 – 00:58:07 Watch: HIGHLIGHTED SPEAKER – Mr. Adam Boehler, MBA: Chief Executive Officer of the new U.S. International Development Finance Corporation (DFC)
00:58:07 – 01:11:38 Watch: HIGHLIGHTED SPEAKER – Michelle McMurry-Heath, M.D., PH.D: President and Chief Executive Office of Biotechnology Innovation Organization (BIO)
01:11:38 – 01:26:25 Watch: BARDA DIRECTOR’S UPDATE – Dr. Gary Disbrow: Acting Director, Biomedical Advanced Research and Development Authority (BARDA)
01:26:25 – 01:35:59 Division of Influenza and Emerging Infectious Diseases (IEID)
Dr. Robert Johnson, Director
01:35:35 – 01:40:38 Division of Detection, Diagnostics, & Devices Infrastructure (DDDI)
Mr. Rodney Wallace, Director
01:40:38 – 01:49:00 Division of Research, Innovation, and Ventures (DRIVe)
Dr. Sandeep Patel, Director
01:49:00 – 01:57:22 Division of Contract Management & Acquisitions (CMA)
Mr. Enrique Mañán, Acting Direorctor
01:57:22 – 02:08:29 Division of Chemical, Biological, Radiological and Nuclear Medical Countermeasures (CBRN)
Dr. Christopher Houchens, Director
02:10:46 - 02:19:36 pm Quickfire Challenge Winner
02:19:36 - 02:19:36 pm BARDA #MakingCountermeasures
VIDEO
PRESENTATION
BREAKOUT SESSIONS
Session 1 Track 1: CBRN Vaccine Programs: Vaccines - Lindsay Parish, PhD; Antivirals & Antitoxins - David Boucher, PhD; Antibacterials - Brian Tse, PhD.
Session 1 Track 2: Division of Clinical Development Overview - Robert Walker; Clinical Operations Branch - Elizabeth Formentini; Biostatistics Branch - James Zhou; Clinical Operations Branch - Marcy Beth Grace
Session 1 Track 3: Blue Knight Panel - Sparking Innovation to Improve the Nation's Response to 21st Century Health Security Threats: Moderator - Ashley Cecere
Session 1 Track 4: Pharmaceutical Countermeasure Infrastructure: Collaborating with our Manufacturing Partners - Arlene Joyner; The National Biopharmaceutical Manufacturing Partnership (BioMaP) - Tim Belski
Session 2 Track 1: Division of Nonclinical Development Overview - April Brys & Claiborne Hughes & James Little; SARS-CoV-2 Response Planning - James Little; SARS-CoV-2 Model Development and Utilization - Allison Totura; SARS-CoV-2 Assay Development - Ashley Smith; BARDA Nonclinical DevelopmentLooking Forward - Claiborne Hughes
Session 2 Track 2: Thermal Burn Medical Countermeasure Program - Janelle Hurwitz; Reimagining Community Preparedness for Mass Casualty Chemical Incidents - William Coley; Radiological & Nuclear Countermeasures Program - John Esker
Session 2 Track 3: Investing in the Future of Health Security Division of Research Innovation & Ventures (DRIVe) - Sandeep Patel
Session 2 Track 4: Contract Management & Acquisitions: Medicalcountermeasures Support Services (MCM-S) - Jeff Schmidt; DRIVe Acquisitions Team - Matt Clay; Station Support & Administrative Contracting (SSAC) - Roseary Hill; Medical Countermeasures Development (MCM-D) - James Harris
Session 3 Track 1: Influenza and Emerging Infectious Diseases: Vaccines - Armen Donabedian; Therapeutics - Kimberly Armstrong; Pandemic Influenza Vaccine Stockpile - Jonathan Seals;
Session 3 Track 2: Regulatory & Quality Affairs - Nina El-Badry; Emergency Use Authorizations (EUAs) - Susan Hollingsworth; JPEO-CBRND - COL Ryan Eckmeier
Session 3 Track 3: CARB-X and Drive Accelerator Networks Wrap Around Services to Prepare for Competitive Funding Engagements - Cameron Bess and Justin Yang
Session 3 Track 4: Detection, Diagnostics, & Devices Infrastructure (DDDI) Division - Rodney Wallace; COVID-19 Timeline & Contracting Approach - John Lee; COVID-19 Dx Manufacturing Capacity Expansion - Charles Daitch; Diagnostics & Medical Devices (The Other Countermeasures); Keys to a Successful White Paper - Paul Eder; EZ-BAA & BAA Solicitation Updates - Jordan Smith
LIGHTNING TALKS - SESSION 1: VACCINES/THERAPEUTICS
00:00:00 – 00:06:27 Watch: Adaptive Biotechnologies - Understanding Immunity to SARS-CoV-2: The T Cell Side of the Equation
00:06:28 - 00:10:07 Watch: Instanosis Inc. - Ultransensitive SARS-CoV-2 Antigen Detection Using Microbubbling
00:10:08 – 00:15:42 Watch: MeMed - MeMed BV™/Key™: Responding Today, Preparing for Tomorrow. A Host-Protein Test for Combatting Antimicrobial Resistance Plus Biomarkers to Aid in Outbreak Management
00:15:43 – 00:21:13 Watch: The University of Kansas - Development of a Handheld Radiation Bio-Dosimeter for Point-of-Care Use
00:21:14 – 00:26:32 Watch: PhenoMx - Multi-Parametric Quantitative Whole-Body Assessment of COVID-19 Infected Individuals for Risk of Chronic Long-Term Conditions
00:26:33 – 00:31:36 Watch: Promethean LifeSciences - GammaGraft for Burn and Wound Medical Countermeasures Stockpiling
00:31:37 – 00:35:58 Watch: PharmaJet - Needle-free Delivery of Pandemic Vaccines
00:35:59 – 00:41:38 Watch: Vir Biotechnology, Inc - Immunological Tools for Pandemic Preparedness
00:41:39 – 00:47:37 Watch: Autonomous Therapeutics, Inc. - Non-Vaccine, Pan-Genus Prophylactics to Prevent COVID-19 and any Future Beta-Coronavirus Pandemic
00:47:38 – 00:53:56 Watch: Abimmune Biopharma Inc. - Respiviridin: A Universal Prophylactic & Therapeutic Candidate against Covid-19 and other Respiratory Viruses
LIGHTNING TALKS - SESSION 2: DEVICES/DIAGNOSTICS
00:00:00 – 00:05:49 Watch: Biomed Industries, Inc. - What does Covid-19 Virus do to the Brain?
00:05:50 – 00:11:42 Watch: Advanced Innovative Partners/Bio-Nucleonics - Treatment of COVID-19 Virus
00:11:43 – 00:17:28 Watch: HDT Bio Corp. - Development of RNA-based PAMP Plus LION as a Novel Antiviral Therapy to Limit COVID-19
00:17:29 – 00:23:18 Watch: KAER Biotherapeutics Corporation - Therapeutic Surfactant and Biologics Aerosols for the Treatment of Hypoxemia and Respiratory Distress
00:23:19 – 00:28:48 Watch: Zim Biosciences Inc. - A Technology for the Amelioration of Thermal and/or Chemical Insults to Lung Tissue
00:28:49 – 00:33:50 Watch: VitriVax - Thermostable, Single-Shot Vaccine Formulation Platform
00:33:51 – 00:39:43 Watch: FluGen Inc. - M2SR Seroconversion Against H3N2 Proximate & Distant Drift
00:39:44 – 00:45:12 Watch: Virica Biotech Inc. - Viral Sensitizers: Accelerating Vaccine Production and Pandemic Response
00:45:13 – 00:51:05 Watch: Codex DNA - Establishing a Global Network of Vaccine Printers
00:51:06 – 00:57:03 Watch: Persephone Biosciences - Arming the Immune System Using Gut Microbiome Therapeutics to Prevent and Fight SARS-CoV-2

Presented By

Website Refresh - www.medicalcountermeasures.gov is pleased to announce a phased launch of our newly redesigned public website. We are making website improvements to provide a more modern and customer-centric web experience. Over the next several months you will see differences throughout the site while we continue implementing updates. Thank you for your understanding and please let us know if you have any questions: techwatchinbox@hhs.gov